L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
In a double blind controlled study, 14 affectively ill patients (2 bipolars, 12 unipolars) were randomly allocated to L-Deprenil treatment (an irreversible selective MAO-B inhibitor without "cheese effect") and 13 patients (3 bipolars, 10 unipolars) to placebo only. Patients on L-Deprenil showed a significantly greater clinical improvement than placebo patients. A positive relationship was found between clinical improvement and degree of platelet MAO inhibition in patients treated with L-Deprenil.
D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000188:drug therapy; D001792:Blood Platelets / Q000201:enzymology; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000201:enzymology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*
D010627:Phenethylamines; D012642:Selegiline; D008995:Monoamine Oxidase